课题基金 / 基金详情

项目摘要

项目成果

Roger J. Hajjar的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 在西方世界,心力衰竭(HF)的发病率持续上升,与HF相关的发病率和 死亡率仍然高得令人无法接受。相关分子机制的研究进展 心力衰竭提供了许多重要的干预靶点。中的两个严重异常 衰竭的心肌细胞是:1)肌浆网(SR)钙-ATPase(SERCA2a)泵异常 2)SERCA2a表达降低。减少SERCA2a在HF中表达的重要性是 利用实验动物模型和通过基因恢复SERCA2a的许多研究记录 转移显著挽救了HF表型,提高了动物存活率。我们小组的目标是减少 冠脉内携带编码SERCA2a的1型腺相关载体表达SERCA2a (AAV1.SERCA2a)在心力衰竭患者中。在上一个资助期内,我们小组发现- SERCA2a的翻译修饰(PTM)可以显著影响该泵的功能。我们 发现心肌细胞中SERCA2a的水平和活性受小泛素样蛋白的调节 修改器类型1(相扑-1)。研究发现,患者体内SUMO-1水平降低,SERCA2a SUMO化水平降低 人体心肌衰竭。在我们提案的前四年,我们在小鼠研究中表明,AAV- 介导的SUMO-1基因治疗显著提高了SERCA2a的水平和心功能,增加了 小鼠在压力超负荷所致心力衰竭中存活。我们还发现相扑-1基因转移改善了 在衰竭的猪心中,收缩能力和防止左心室扩张。研究发现相思甲基化是一种关键的 调节SERCA2a功能的PTM。也有越来越多的证据表明,除了SUMO化之外,还有其他 心肌细胞中存在氧化、甲基化、硝化、磷酸化和乙酰化等PTMS。这个 SERCA2a不同赖氨酸PTM的串扰和选择性可能是细胞 以时间依赖的方式对不同的刺激做出反应。我们最近的发现表明,SERCA2a SUMO化 与赖氨酸乙酰化/去乙酰化途径密切相关。首先,在HF中,SERCA2a糖基化减少 而在HF的设置下,乙酰化程度增加。第二,SERCA2a乙酰化对 SERCA2a的功能。第三,我们的初步数据显示,乙酰化的减少伴随着 SERCA2a糖基化增加。这些数据表明,乙酰化和乙酰化之间存在平衡。 SERCA2a的总甲基化,在HF中改变。我们建议的主要假设是SERCA2a 乙酰化降低了SERCA2a的功能,减少了SERCA2a的糖基化,导致病情恶化 心功能在心衰时的变化。实现这些目标将提供对以下机制的新见解 赖氨酸介导的SERCA2a在心衰时的调节作用。这项研究将提供一种新的战略 操纵SERCA2a翻译后修饰,最终可能导致新的治疗剂。
英文摘要
Abstract The incidence of heart failure (HF) continues to increase in the Western world and HF related morbidity and mortality remain unacceptably high. Advances in understanding the molecular mechanisms that are associated with cardiac failure have offered a number of important targets for intervention. Two critical abnormalities in failing cardiomyocytes are: 1) an abnormal sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) pump function and 2) decreased expression of SERCA2a. The importance of reduced SERCA2a expression in HF is documented in many studies utilizing experimental animal models and restoration of SERCA2a by gene transfer significantly rescues HF phenotype and increases animal survival. Our group has targeted the reduced expression of SERCA2a by delivering intracoronary adeno-associated vector type 1 encoding SERCA2a (AAV1.SERCA2a) in patients with heart failure. During the previous funding period, our group found that post- translational modifications (PTMs) of SERCA2a can significantly affect the function of this pump. We discovered that the levels and activity of SERCA2a in cardiomyocytes are modulated by small ubiquitin-like modifiers type 1 (SUMO-1). Reduced SUMO-1 levels and decreased SERCA2a SUMOylation were found in failing human myocardium. In the first four years of our proposal, we showed that in murine studies, AAV- mediated SUMO-1 gene delivery significantly improved SERCA2a's levels, cardiac function and increased mouse survival in pressure overload-induced HF. We also found that SUMO-1 gene transfer improved contractility and prevented left ventricular dilation in failing pig hearts. SUMOylation was found to be a critical PTM that regulates SERCA2a function. There is also growing evidence that aside from SUMOylation other PTMs such as oxidation, methylation, nitration, phosphorylation and acetylation occur in cardiac cells. The crosstalk and selectivity of different lysine PTMs of SERCA2a could be an important mechanism for cells to respond to different stimuli in a time-dependent fashion. Our recent findings show that SERCA2a SUMOylation is closely linked to lysine acetylation/deacetylation pathways. First, SERCA2a SUMOylation is decreased in HF while acetylation is increased in the setting of HF. Second, SERCA2a acetylation negatively impacts SERCA2a's function. Third, our preliminary data show that the reduction of acetylation is accompanied by increased SUMOylation of SERCA2a. These data suggest that there is a balance between acetylation and SUMOylation of SERCA2a, which is altered in HF. The major hypothesis of our proposal is that SERCA2a acetylation decreases SERCA2a function and reduces SUMOylation of SERCA2a leading to worsening cardiac function in the setting of HF. Achieving these aims will provide new insights into the mechanisms of lysine-mediated SERCA2a regulation in the setting of HF. This study will provide a novel strategy for manipulating SERCA2a post-translational modifications that may ultimately lead to novel therapeutic agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small Molecule Therapy for the Treatment of Heart Failure
  • 批准号:
    9335758
  • 项目类别:
  • 资助金额:
    $55.06万
  • 财政年份:
    2017
  • 负责人:
    Roger J. Hajjar
  • 依托单位:
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
Role of miR25 in Heart Failure
海外基金